event-trade登录编辑
PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 14:21:00·⟳ 抓取 14:21:15 +15s·⚡ 决策 08-24 16:58:35 +2h37m·64.2 天前

SBS再次提醒CAPR投资者参与证券欺诈集体诉讼,未披露新的公司事实

本次PR Newswire稿件相对2026-08-14同一律所提醒和此前CAPR/FDA公开事实没有新增可交易信息,且律所招揽首席原告本身不等于公司新增净损害。

📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES,…
不做 Capricor Therapeutics, Inc.(CAPR.US)
不做Capricor Therapeutics(CAPR.US):本条是律所重复提醒,核心诉讼和Deramiocel/FDA负面背景已提前公开,未新增足以开空或做多的事实。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

事件正文是SBS Law对CAPR证券欺诈诉讼的投资者提醒,核心事实已在至少2026-08-14同类稿件中出现,诉讼基础又来自7月FDA顾问委员会负面投票与Deramiocel BLA争议。当前没有新裁定、新监管动作、新FDA结论或新增金额,做空催化不够新、不够强;做多也没有正向增量,因此不做。

🔎 新鲜度:最早出现 2026-08-14 · 扩散 medium · price-in 风险 high ↗ ↗ ↗

消息传播链

  1. 2026-07-30官方确认/否认Capricor Therapeutics/SEC 8-K一手源原文 ↗
    公司披露FDA顾问委员会认为现有证据不支持Deramiocel治疗DMD心肌病有效性,构成诉讼指控背景但不是本次律所提醒首发。
  2. 2026-08-14 10:26 ET首发GlobeNewswire/SBS Law非一手原文 ↗
    同一SBS Law提醒已发布,包含CAPR、同一class period、同一首席原告截止日和同一诉讼要点。
  3. 2026-08-24 02:21 ET财经媒体扩散PR Newswire/SBS Law非一手原文 ↗
    本次抓取稿为律所提醒的再次分发,未见新增法院、监管或公司事实。

主要风险

  • 若后续出现法院受理关键进展、FDA正式拒批/批准或公司披露Deramiocel监管结果,需要重新研判。

反向证据

  • 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
    真正的强负面事实是7月30日FDA顾问委员会负面投票,已提前公开;本次律所提醒没有新增拒批、处罚或裁判。
    检索:Capricor Therapeutics Deramiocel FDA advisory committee July 2026 BLA company update 原文 ↗
  • 做空前查反向 · 来源 web · 日期 2026-08-14 · 影响 invalidates
    同一律所、同一诉讼提醒已在8月14日发布,削弱8月24日作为新做空催化的边际价值。
    检索:CAPR securities fraud lawsuit SBS Law August 14 2026 same class period September 28 2026 原文 ↗

先例如何影响了这次决策

对本次决策的影响:先例不足未改变结论;结论由同一SBS提醒已提前发布且本条无新增事实决定。

方向:未使用外部先例校准交易方向,因为本次在事件身份层面已判定为重复律所提醒、无新增事实。

涨幅量级:无可用高相似先例用于幅度校准。

形态:证券诉讼律所提醒常作为既有下跌后的追索招揽信息出现,但本轮未完成工具化事件研究,不能量化胜率。

原文全文

展开原文 · 2,837 字
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 24, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。